Nanobiotix S.A. (NBTX) Form 6-K — Oct 26, 2026
Nanobiotix announced final data from the Phase 1 Study 1100 evaluating JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in anti-PD-1-resistant advanced primary cutaneous melanoma, presented at ESMO 2026. In 24 heavily pre-treated patients, the study showed a 41.7% overall response rate including 4 complete responses, a 75% disease control rate, 6.9-month median PFS, and 17.8-month median overall survival, with an acceptable safety profile and no new safety signals. Responses were seen in both injected and non-injected lesions, and exploratory cytokine analysis showed IL-1β as the most increased plasma cytokine, suggesting treatment-induced immune activation.
Key figures
- Orr
- 41.7% (10/24)
- Patients
- 24
- Median pfs months
- 6.9
- Complete responses
- 4
- Injected lesion orr
- 45.8%
- Disease control rate
- 75% (18/24)
- Non injected lesion orr
- 30.0%
- Median overall survival months
- 17.8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.